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Evnen til å identifisere lukter studert hos friske individer, personer med 
mild kognitiv svikt og Alzheimers sykdom 
 
Bakgrunn: Luktidentifikasjon er evnen til å oppfatte og navngi en lukt riktig. 
Allerede i midten av 1970-årene ble de første studiene publisert som viste at evnen 
til å lukte er svekket ved nevrodegenerative sykdommer (Ansari og Johnson og 
Waldton). Majoriteten av pasienter med amnestisk mild kognitiv svikt (aMCI) og tidlig 
Alzheimers sykdom er vist å få redusert lukteevnen, særskilt evnen til å identifisere 
lukter. Siden områder i hjernens temporallapp er sentral både i luktprosessering, 
samtidig som entorhinal cortex er det område som trolig rammes tidligst ved 
Alzheimers sykdom, så er det av stor interesse å undersøke lukteevnen hos denne 
pasientgruppen. For å vurdere nytten av testing med lukt identifikasjon i klinikken, 
trenger vi en bedre forståelse av de nevronale prosessene som ligger til grunn for 
lukt identifikasjon i den menneskelige hjerne. I tillegg trenger vi standardiserte 
luktetester for bruk i Norge som er tilpasset norske forhold. Dette bør være tester 
som er enkle å administrere, som koster lite og tar kort tid å gjennomføre. 
 
Formål: Denne avhandlingen har tre hovedmål. Det første målet var å undersøke 
nytten av kommersielle luktetester som "the Brief Smell Identification Test" (B-SIT), 
en modifisert versjon av B-SIT og "the Sniffin Sticks Identification Test" (SSIT) i 
norske populasjoner for å kunne skille pasienter med tidlig Alzheimers sykdom og 
aMCI fra friske kontroller. Det andre målet var å undersøke hvilke hjerneområder 
som aktiveres hos unge friske mennesker under vellykket identifisering av lukter. Det 
siste målet var å studere hvordan volumene av ulike strukturer i hjernen samvarierer 
med evnen til å identifisere lukter hos pasienter med mild grad av demens ved 
Alzheimers sykdom og friske sammenlignbare kontroller. 
 
Metoder: Artiklene i avhandlingen baserer seg på fire eksperimentelle studier i fire 
ulike populasjoner. Det er gjennomført psykofysiske luktetester i alle de fire 
populasjonene, men det er studiene referert i artikkel I og artikkel II som i hovedsak 
beskriver luktetestens metodikk. I artikkel III har vi brukt funksjonell magnetisk 
resonans bildedannelse (fMRI) for å studere aktiveringsmønsteret i hjernen ved 
luktidentifikasjon hos friske unge personer. Luktstimuleringen i skanneren ble gitt 
ved hjelp av et olfaktometer. I artikkel IV har vi brukt strukturell magnetisk resonans 
bildedannelse (strukturell MRI) for å studere assosiasjoner mellom volumer av ulike 
hjernestrukturer og evne til å identifisere lukter. Dette ble undersøkt hos pasienter 
med en aMCI og mild grad av demens ved Alzheimers sykdom og friske eldre 
personer. 
 
Hovedfunn: Studie I demonstrerer at B-SIT er velegnet for bruk i Norge til å skille 
pasienter med Alzheimers sykdom (hvor noen av pasientene var i tidlig stadium) fra 
friske personer. Studie II viser at en modifisert versjon av testen B-SIT, er en like 
god test som den originale B-SIT, samtidig som den trolig kan være en bedre test til 
bruk i generelle populasjoner. Funnene fra Studie III indikerer at entorhinal cortex og 
hippocampus er sentrale områder i hjernen som aktiveres spesifikt når friske unge 
personer klarer å identifisere lukter. Studie IV demonstrerer at pasienter med aMCI 
eller tidlig Alzheimers sykdom som har relativt intakt luktefunksjon (ut fra både B-SIT 
og SSIT), har større volum av hippocampus enn de med redusert 
luktidentifiseringsevne.  
 
Konklusjon: Våre funn viser at lukteskreening testene B-SIT og SSIT er godt 
tilpasset for bruk i Norge, og at en modifisert versjon av B-SIT vil være en like god 
test som den originale B-SIT. De nevronale prosessene som ligger til grunn for 
luktidentifikasjon i den menneskelige hjerne, ser ut til å inkludere et helt nettverk av 
strukturer, hvor særskilt entorhinal cortex og hippocampus er sentrale strukturer for 
at friske unge personer klarer å navngi lukter riktig. Luktetestene kan hjelpe til å 
skille ut de pasienter som er mer langtkommet i utviklingen av Alzheimers sykdom, 
fordi gruppen med redusert lukteidentifikasjonsevne hadde signifikant mer redusert 
hippocampus volum enn de med intakt lukteidentifikasjonsevne. Hva vi har funnet i 
studiene, har gitt økt kunnskap om nytten av bruk av luktetester i norske 
populasjoner, og ny kunnskap om de nevronale prosessene som ligger til grunn for 
luktidentifikasjon i den menneskelige hjerne. 
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1.0. Introduction 
 
Loss of odor identification (OI) is often associated with neurodegenerative diseases 
such as Alzheimer’s disease (AD). The utility of OI tests as clinical tools depends on a 
better understanding of the neuronal processes underlying OI in the human brain. 
However, the sense of smell is influenced by factors such as experience and culture, 
and feasible commercial olfactory screening tools need to be validated for use in the 
population that is to be tested.  
 
1.1. The human olfactory system 
 
The human olfactory system is the route from the olfactory epithelium via the 
olfactory bulbs to the higher olfactory regions of the brain. Olfaction has immediate 
access to the olfactory cortex (only two synapses) without relay in the thalamus. 
Substances called odorants are capable of activating the olfactory system. An odor is 
defined as the sensation created by the olfactory organs. How the olfactory system 
decodes information from chemical compounds to produce odor perception is a 
complex process. Olfactory function is organized in both a parallel and hierarchical 
manner, depending on the character and complexity of the odor task. The 
hierarchical nature of olfactory processing is from a lower level of perception up to a 
higher level of perception, to produce the odor percept. Odor detection is the degree 
of presence of an odorant. This sensory process can be assessed by exposure to low 
odor concentrations, and determining the threshold at which the odor is detectable. 
The term higher olfactory function is used to describe brain functions that combine 
cognition and olfaction, and includes three main concepts. Firstly, odor recognition 
involves matching input with stored information. It is based on the ability to 
remember odors that have previously been presented. Secondly, odor discrimination 
is the ability to differentiate between two or more odorants. Thirdly, the most 
complex process is OI, the assignment of meaning and naming of an odor. Other 
aspects of the olfactory function often studied are intensity, pleasantness, quality, 
familiarity or edibility judgment. 
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1.1.1.    The peripheral olfactory system 
 
Odorants which consist of physiochemical molecules enter the nose through the 
nostrils into the upper part of the nasal cavity where the olfactory epithelium is 
located. The olfactory epithelium measures about one square centimetre on each 
side and lies in the roof of the nasal cavity. The olfactory epithelium consists of three 
distinct types of cells: olfactory receptor cells, supporting cells and basal cells. Unlike 
other neurons in the adult nervous system, the olfactory receptor neurons have the 
ability to regenerate and are unmyelinated. There are several million bipolar receptor 
cells, and these cells have cilia branching out into the layer of mucosa in the 
superficial layer of the epithelium. The odorants react with receptors, called odor-
binding proteins, located on the cilia. Most odors are complex mixtures of many 
components. Each olfactory receptor cell processes only one type of odorant receptor 
(Buck and Axel, 1991), and each receptor is highly specialized and can detect a 
limited number of odorant substances (Duchamp-Viret et al., 1999). Thus each 
receptor may serve as one component of the code for many odorants and allow for 
the discrimination of a large number of different odorants (Kandel, 2000). Binding of 
odorants to these receptors causes activation of the enzyme adenylate cyclase, 
which converts adenosine triphosphate (ATP) to cyclic adenine monophosphate 
(cAMP), cAMP then causes sodium channels to open leading to depolarization of the 
cell membrane. If the activation is sufficient to cause an action potential, the 
information from the stimulus will be passed to the central nervous system (CNS).  
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Figure 1. The peripheral part of the olfactory system (Figure adapted from Zelano 
2005).  
 
The olfactory cells of the epithelium are bipolar neurons which form the olfactory 
nerve, cranial nerve I. Once the axons leave the olfactory epithelium they collect into 
20 or more bundles, and project ipsilaterally, and reach the olfactory bulbs. The 
olfactory bulbs, one in each hemisphere, are located under the ventral surface of the 
frontal lobes in the humans and contain around 50 000 mitral cells. Both inhibitory 
and excitatory processing takes place in the olfactory bulb. The granule cells are 
inhibitory interneurons, and periglomerular cells are involved in lateral inhibition 
while the excitation is from the mitral cells. The olfactory bulbs contain small 
structures called glomeruli where the axons from the olfactory neurons enter. The 
olfactory bulbs have about 2000 glomeruli each. The input from all neurons 
expressing the same receptor is collected by a single glomerulus. Axons from 
second-order neurons in the olfactory bulb form the olfactory tract, which projects 
directly to the primary olfactory structures in the brain (Hatt, 2004, Paysan and 
Breer, 2001). 
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1.1.2.    The central olfactory system 
 
The olfactory cortex is usually described as part of the allocortex, a cortex which is 
thinner and structurally less complex, with only three layers, compared to the six 
layers of the neocortex (Price, 1990). Our understanding of neural processing of 
olfactory stimuli is primarily based on animal studies (insects and mammals) 
(Carmichael et al., 1994, Haberly and Price, 1978, Insausti et al., 2002, Price, 
1990).The areas receiving direct input from the olfactory bulb are called the primary 
olfactory cortex or areas (Price, 1990). The primary olfactory cortex encompasses 
five structures; the anterior olfactory nucleus, the olfactory tubercle (in humans this 
is an area perforated with blood vessels and is called SPA), the piriform cortex, parts 
of the amygdaloid complex (including periamygdaloid cortex and the anterior cortical 
nucleus of the amygdala), and the rostral part of entorhinal cortex. All of the 
structures mentioned above (except the olfactory tubercle) project back to the 
olfactory bulb. These primary olfactory cortical structures have several intra-cortical 
connections with each other (See Figure 2). The connections for piriform cortex, the 
amygdaloid complex and entorhinal cortex will be described below. 
 
The piriform cortex is well defined in humans (Hummel et al., 2009, Zelano et al., 
2005), and is part of the allocortex. The piriform cortex is the primary target of 
projections from the olfactory bulb (Kay and Freeman, 1998), and the anterior 
piriform cortex receives the majority of the direct projections from the olfactory 
bulbs. Piriform cortex also receives input from the orbitofrontal cortex, insula, basal 
forebrain, brainstem, thalamus and hypothalamus (Haberly and Price, 1978, 
Kowianski et al., 1999). The piriform cortex is a three-layered allocortical structure, 
where Layer I contains the dendrites from the pyramidal cells, and receives axonal 
endings from the lateral olfactory tract (Hawkes, 2009). Studies in rats indicate that 
Layer II contains tightly arranged pyramidal cell bodies, while Layer III contains 
more dispersed pyramidal cell bodies (Haberly and Price, 1978). Inhibitory 
interneurons are also found in Layer I and III. The piriform cortex is divided into a 
posterior (temporal) and anterior (frontal) part which have been found to have 
different specialized functions (Gottfried et al., 2006, Howard et al., 2009, Li et al., 
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2006, Li et al., 2008). Further projections from the piriform cortex go to the 
secondary olfactory structures including hypothalamus, orbitofrontal cortex, insula, 
and the medial dorsal nucleus of the thalamus (Gottfried et al., 2006, Howard et al., 
2009). 
 
The amygdaloid complex lies rostral to the hippocampus, and contains three 
functional subdivisions. The anterior cortical nucleus of the amygdaloid complex, and 
the periamygdaloid cortex are part of the corticomedial nuclei and receive direct 
projections from the olfactory bulbs (Price, 1990). The periamygdaloid cortex and the 
anterior cortical nucleus project back to the piriform cortex, and also to secondary 
olfactory structures; insula, the basal ganglia, thalamus, hypothalamus and 
orbitofrontal cortex (Doty, 2003, Gottfried et al., 2002, Kowianski et al., 1999, Wyss, 
1981).  
 
The primary olfactory region in the rostral (anterior) entorhinal cortex receives direct 
projections from the olfactory bulbs (Amaral et al., 1987, Insausti et al., 2002, Price, 
1990). Entorhinal cortex has intra-connections (whether these connections are 
reciprocal projections are unknown) with the other primary olfactory regions, 
including the amygdala, olfactory tubercle and anterior olfactory nucleus (Kowianski 
et al., 1999, Wyss, 1981). The olfactory information passes so to the anterior part of 
the hippocampus with direct projections from entorhinal cortex (Insausti et al., 
2002). 
 
The primary olfactory cortex projects to secondary olfactory structures, for example 
hippocampus, orbitofrontal cortex, insula and thalamus. A network of structures 
outside the core regions are often involved, determined by the nature of the 
olfactory task (Dade et al., 1998, Savic et al., 2000, Savic, 2002). Hippocampus is 
one of the secondary olfactory structures, and receives strong afferent input from 
the entorhinal cortex (Insausti et al., 2002). Both CA1 and the subiculum project 
back to the entorhinal cortex. Further details concerning the connections of the 
secondary olfactory structures are not described here, please see (Amaral et al., 
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1987, Gottfried et al., 2006, Howard et al., 2009, Insausti et al., 2002, Insausti et al., 
1987, Price, 1990). 
 
 
 
Figure 2. Central connections of the olfactory system (adapted from Zelano and 
Sobel 2005). The red arrows are projections from the olfactory bulb to the primary 
olfactory cortices, and the grey arrows are reciprocal connections to the olfactory 
bulb. Each primary olfactory cortical structure has a uniqe box and arrow color. The 
secondary olfactory structures are color-coded as green boxes. Green arrows indicate 
reciprocal connections from secondary to primary olfactory structures, or to other 
secondary structures.  
 
1.1.3.    Neuroimaging of olfactory function 
 
Evidence from imaging studies has also elucidated the anatomy of human olfaction. 
Zatorre and colleagues were the first to demonstrate odorant-induced activity in the 
piriform cortex in humans, and in 1994 Koizuka and colleagues did the same with 
functional magnetic resonance imaging (fMRI) (Koizuka et al., 1994, Zatorre et al., 
1992). Zatorre et al. (1992) investigated whole brain activation following odor 
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stimulation in 11 healthy subjects. The results from the PET-imaging were bilateral 
activation of piriform cortex, right orbitofrontal cortex, bilaterally insula and medial 
frontal cortices. Koizuka and colleagues obtained a significant increase in cerebral 
blood flow in the piriform cortex, orbitofrontal cortex, and inferior medial frontal lobe 
during odor stimulation (Koizuka et al., 1994). Since these pioneer studies, the 
olfactory structures have been mapped in humans with imaging methods, with more 
or less success. 
 
The areas most often activated during passive smelling tasks are called the olfactory 
core regions (Savic, 2002).  In general, activated areas observed with neuroimaging 
methods vary, perhaps caused by the use of different odors and odor tasks. 
Neuroimaging (fMRI and PET) of passive smelling of odors shows activation of the 
piriform cortex (Bengtsson et al., 2001, Gottfried et al., 2006, Howard et al., 2009, 
Savic et al., 2000, Zatorre et al., 1992, Zelano et al., 2005), amygdala (Royet et al., 
2000, Savic et al., 2000, Zald and Pardo, 1997), orbitofrontal cortex (Bengtsson et 
al., 2001, Savic et al., 2000, Zald and Pardo, 1997, Zatorre et al., 1992), insular 
cortex (Bengtsson et al., 2001, Savic et al., 2000, Zatorre et al., 1992), and the 
anterior olfactory nucleus (Sobel et al., 1998). 
 
Savic and colleagues reported further that odor induced brain activity depends on the 
nature of the specific odor task, whether or not a more widely distributed network of 
brain regions located outside the olfactory core regions also becomes engaged (Dade 
et al., 1998, Savic et al., 2000, Savic, 2002). Other brain-structures often activated 
during olfactory tasks are thalamus (Savic et al., 2000, Sobel et al., 2000), cingulate 
cortex (Savic et al., 2000; 2002), and cerebellum (Ferdon and Murphy, 2003, Savic, 
2002). Imaging evidence describing the role of piriform cortex, entorhinal cortex and 
hippocampus in olfactory function will be outlined in the following section. 
 
The anterior piriform cortex is considered to be involved in encoding of odorant 
structure (Gottfried et al., 2006). The posterior piriform cortex on the other hand, 
encodes the unique identity of an olfactory percept, and seems to have learning-
induced neural plasticity (Gottfried et al., 2006, Howard et al., 2009). Humans are 
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exposed to odors continuously, but are able to select the odors that are most 
important and requring attention. Zelano and colleagues reported attention-
dependent and attention-independent sub-regions (frontal and temporal part) in the 
piriform cortex (Zelano et al., 2005). Odorless sniffing has also been demonstrated to 
activate primary as well as secondary olfactory structures (Kareken et al., 2004, 
Simonyan et al., 2007, Sobel et al., 1998), and is often reported to lead to piriform 
cortical activity (Kareken et al., 2004, Koritnik et al., 2009, Sobel et al., 1998), but 
seldom in entorhinal cortex (Koritnik et al., 2009).  
 
Relatively few of the olfactory neuroimaging studies have reported activation of the 
entorhinal cortex during olfactory tasks (Poellinger et al., 2001, Sobel et al., 1998, 
Suzuki et al., 2001, Wang et al., 2005, Zald and Pardo, 2000, Zatorre et al., 1992). 
In humans, olfactory input projects to the limited part of the anterior entorhinal 
cortex (Brewer, 2006), which may explain the weak or often lacking activation of 
entorhinal cortex in imaging studies.  
 
The olfactory system is the sensory system with the most direct access to the 
hippocampus. Several studies of olfaction, using a wide variety of odorants and tasks 
have reported hippocampal activity, but lateralization and location along the anterior-
posterior axis of the hippocampus varies (Bengtsson et al., 2001, Cerf-Ducastel and 
Murphy, 2001, Levy et al., 1997, Poellinger et al., 2001, Small et al., 1997, Tabert et 
al., 2007, Zald and Pardo, 2000, Zatorre et al., 2000). It is suggested that the 
hippocampus at the longitudinal axis (anterior to posterior) has functional 
differentiation (Small, 2002), the posterior part receiving the input from the visual 
cortex, while the olfactory input projects to the anterior part (Brewer, 2006, Small, 
2002).  
 
Neuroimaging evidence for OI more specifically, will be discussed in section 1.2. 
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1.2.  Odor identification (OI) 
 
OI is a higher order odor function usually defined as the ability to name an odor. 
Johnson and colleagues suggested another definition of OI as the ability to identify 
the odor by any means, i.e. just to know what it is and not necessarily label it 
(Jonsson et al., 2005). OI involves both sensory and cognitive functions, and consists 
mainly of three processes. Firstly, OI requires a certain degree of olfactory sensitivity 
to detect the odor. Secondly, accurate recognition of the odorant is necessary (Doty, 
2005), and lastly a search through semantic stores for the appropriate verbal label is 
required in order to name the odorant (Dempsey and Stevenson, 2002). Thus, at a 
conscious, perceptual level we perceive a holistic odor object based on the 
information from these combined processes (Wilson, 2006).  
 
OI is categorized under semantic memory, but also rely on episodic memory. These 
are two types of declarative memory, supporting conscious recollection of the past 
and depend on the integrity of the medial temporal lobe (MTL) (Squire and Zola-
Morgan, 1991). Episodic memory refers to memory for personally experienced events 
and experiences (Tulving, 1983), and semantic memory refers to the capacity for 
recollecting facts and our general knowledge about the world. OI relies on semantic 
memory, since the task depends on previously learned odor-name associations and 
successful retrieval of these associations (Murphy et al., 1997, Oberg et al., 2002). A 
more recently study also showed that semantic memory contributed significantly on 
OI performance in healthy individuals (Hedner et al., 2010). However, the semantic 
representation of odors is considered to depend not only on verbalization, but also 
on the context the odor occurred in, and here episodic memory comes in. In 1890 
William James noted that "every perception is an acquired perception", and was 
referring to the odor object perception which is formed into a percept influenced by 
past experience, context, attention and expectation (Wilson, 2006). Thus odors are 
believed to be organized in an associative network in terms of the episodes that they 
relate to in an individual’s past (Engen, 1987, Herz, 2003). In addition, behavioural 
studies indicate significant interactions between OI, semantic knowledge, odor 
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memory and verbalization (Larsson, 1997, Murphy et al., 1991, Perkins and Cook, 
1990, Royet et al., 2004). 
 
Humans are in general good at detecting odors and can discriminate between tens of 
thousands of odors (Doty, 1992). On the other hand, naming odors spontaneously is 
a very difficult task (Schab, 1991). In an un-cued OI task, a person with a normal 
sense of smell is seldom able to identify familiar odors in >50 % of the cases 
(Engen, 1987, Jonsson and Olsson, 2003). Often people are able to smell an odor 
and recognize it as familiar, but are still unable to produce a specific verbal label. 
This is described as the `tip of the nose phenomenon´ (Lawless and Engen, 1977). 
Typically, when given the name of the odor afterwords, the odor is recognized 
immediately (Lawless and Engen, 1977). Why humans perform so poorly in OI tasks 
could be caused by the way olfactory information is stored in the brain. It is thought 
that the odor percept is stored in the brain as a holistic percept, which seems to rely 
on several structures in the brain as well as the peripheral part of the olfactory 
system. Olfactory testing of the most famous patient in neuroscience, Henry Gustav 
Molaison or H.M., in the 1980s gives important information with regard to the brain 
structures supporting OI (Eichenbaum et al., 1983). Patient H.M. underwent bilateral 
resection of the anterior hippocampi, amygdalae, and entorhinal cortices due to 
intractable seizures, and became impaired in discriminating between different odor 
qualities as well as OI, while his ability to discriminate odor intensity remained intact 
(Eichenbaum et al., 1983).  
 
Below, the role of amygdala, hippocampus and entorhinal cortex in OI will be 
highlighted based on evidence from studies in animals, neuroimaging and brain 
autopsies in humans. 
 
Amygdala is often activated in olfactory tasks, and is one of the olfactory core 
regions receiving direct projections from the olfactory bulb. Studies report that the 
amygdala responds to odor intensity (Anderson et al., 2003) and valence (Zald and 
Pardo, 1997), as well as memory (components of smell). Furthermore, amygdala 
plays a role in the emotional processing of olfactory stimuli. A Positron Emission 
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Tomography (PET) study has shown that aversive odors activate the amygdala (Zald 
and Pardo, 2000). However, as far as we know, no evidence supports a specific role 
of amydala in OI. 
 
Historically, in the early 1900’s Broca and Edinger traced direct connections of the 
olfactory tract into the hippocampus, though later this result was rejected (Brodal, 
1947). However, the shortest pathway from a sensory organ to the hippocampus, 
measured in number of synapses, is found for olfaction. Imaging evidence suggests 
that the hippocampus is specifically involved in higher level processing of olfactory 
information (Staubli et al., 1984). Wilson and colleagues demonstrated that early OI 
deficits related to AD pathology are correlated with the number of tangles in 
entorhinal cortex and hippocampus (Wilson et al., 2007). However, no imaging 
studies of OI have reported activation in the entorhinal cortex yet. Evidence for the 
role of hippocampus in OI is also sparse. However, one study has reported increased 
activation in right hippocampus during OI in healthy elderly individuals (Suzuki et al., 
2001), and another study reported activation in the subiculum, part of the 
hippocampal formation, in young healthy females during discrimination of odor 
quality (Savic et al., 2000). Murphy et al. 2003 demonstrated that left hippocampal 
volume loss was correlated with poorer OI ability in patients with AD (Figure 2) 
(Murphy et al., 2003), and they assumed a left hemispheric superiority for verbally 
mediated olfactory tasks (Murphy et al., 2003). However, a structural Magnetic 
Resonance Imaging (MRI) study showed a relationship between OI function in 
hippocampus bilaterally (Lojkowska et al., 2011). Lojkowska and colleagues showed 
in Mild Cognitive Impairment (MCI) patients (Figure 1) that there was a correlation 
between progressing deterioration in cognitive function, OI and decreased volume of 
the hippocampus (Lojkowska et al., 2011).  
 
The hippocampus is well known to be particularly important for encoding, retrieving 
and associating information from all the senses. Some studies have reported that the 
hippocampal region is important for both episodic and semantic memory (Manns et 
al., 2003, Squire and Zola, 1998). However, the majority of studies report that it is 
mainly episodic memory which relies on the hippocampal region, and not semantic 
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memory (Nadel and Moscovitch, 1997, Reilly, 2001, Tulving and Markowitsch, 1998). 
Semantic processing is reported to be located in the posterior temporal lobe and 
ventrolateral prefrontal cortex (Badre et al., 2005, Binder et al., 2009, Bookheimer, 
2002, Gough et al., 2005, Thompson-Schill et al., 1998, Wig et al., 2005), and Brocas 
area`s (Muller et al., 2003). Activation of areas relating to semantic processing is 
also found in OI imaging studies (Kareken et al., 2003). 
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Box 1:  Dementia and Mild Cognitive Impairment (MCI) 
 
Dementia
Dementia is an "umbrella" term for a set of symptoms including loss of memory, mood 
changes, and problems with communication and reasoning, caused by various diseases and 
conditions that results in damaged brain cells or connections between brain cells. When
making a diagnosis of dementia, the DSM-IV or ICD-10 criteria are used 1. To meet these
criteria the cognitive impairment should be of such a degree that it leads to dysfunction in 
activities of daily living. Another criterion is that the person in question should have changed
his/her behaviour.
AD is the most common cause of dementia and the most frequently occurring 
neurodegenerative disease. Estimates from 2006 report that 65 000 persons in Norway suffer 
from dementia and that about 10 000 new patients become demented every year 2. If the 
number of elderly continues to increase, there is likely to be a doubling of the number of 
patients with dementia by the year 2040 3. 
Mild Cognitive Impairment
The concept of mild cognitive impairment (MCI) has evolved to describe the transitional state 
between normal cognitive function and dementia 4, and the cognitive deficit is not severe 
enough to meet the criteria for dementia 5. To use the term cognitive impairment should not 
lead to dysfunction in activities of daily living.
MCI has been distinguished into several subgroups, the most common being amnestic MCI 
(aMCI) characterized by memory deficits and complaints 6. In 2011 a new concept was 
suggested, "MCI due to AD" to describe those symptomatic but non-demented individuals 
whose primary underlying pathophysiology is similar as in AD 7. 
Having MCI is a risk for developing AD 8. Persons with memory impairment, for instance 
subjects with aMCI, have an annual risk of progression to AD of 10-15 %, i.e. in five years 
about 50 % of all aMCI individuals have developed dementia 8,9. 
In MCI patients the reduction in structural brain volume seems to be moderate compared to 
AD patients 10. A reduction in overall volume in entorhinal cortex and hippocampus in MCI 
shows moderate to strong association with conversion to AD 11,12,13,14.
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Box 2:  Alzheimer’s Disease (AD) 
 
Alzheimer`s Disease
Alzheimer’s disease (AD) is the most common neurodegenerative disorder in humans, and is 
the major cause of dementia in the elderly population. It is a progressive and degenerative 
illness that leads to death, and it is characterized clinically by a gradual onset and progression
of memory loss. 
Amyloid plaques, neurofibrillary tangles, neurodegeneration and inflammation are well-
established hallmarks of AD. Neurofibrillary tangles are composed of paired helical filaments of
hyperphosphorylated tau protein, whereas the main protein component of senile plaques is β–
amyloid. Amyloid deposition occurs early, and is part of the earliest changes to take place in  
the development of AD 1. 
According to NINCDS-ADRDA criteria of AD a pathological diagnosis is possible only at 
autopsy, and this are the criteria most frequently used for the diagnosis of AD 2.The 
NINCDS-ADRDA criteria classify AD based on degree of certainty and whether AD is 
associated with other disease processes. However, in 2011 the National Institute on Aging 
and the Alzheimer´s Association recommended new criteria to identify the disease also at a 
preclinical stages of AD 3. To date, these criteria are only recommended for research 
purposes.
The pattern of neurodegeneration seen in early AD using structural MRI is similar to the   
progression of neurofibrillary pathology which usually begins and is ultimately most severe in
MTL 1,4, particularly the anterior part of the entorhinal cortex and hippocampus 5,6. Later (i.e. 
when subjects are in the clinical MCI phase), the disease spreads to the basal temporal lobe 
and paralimbic cortical areas such as the posterior cingulate gyrus and precuneus. 
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conversion to Alzheimer`s disease Neuroimage 60, 1622-1629.
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1.3.  Olfactory dysfunction 
 
Olfactory dysfunction can be caused by peripheral or central damage to the olfactory 
system. Anosmia is the total loss of olfactory function. This is a state with an inability 
to perceive odors, and can be either temporary or permanent. It is possible to be 
anosmic to one specific odor, this is called specific anosmia. Hyposmia, is a 
decreased ability to smell, on the other side is hyperosmia an increased ability to 
smell. Other technical terms to describe olfactory dysfunction exist, but we use the 
terms hyposmia and anosmia in the text. About 5 % of the general population is 
estimated to have no sense of smell (anosmia), and about 20 % of the general 
population has impaired olfactory function (hyposmia) (Bramerson et al., 2004, 
Landis et al., 2004, Murphy et al., 2002).  
 
However, the majority of anosmia or hyposmia cases in the clinic are caused by 
upper respiratory infections (Jafek et al., 1990), head trauma (Doty et al., 1997b) 
nasal and sinus disease (Doty and Mishra, 2001), including nasal surgery, tumors in 
the nose and the most can be expected to reflect significant damage to the olfactory 
epithelium (Deems et al., 1991, Mott and Leopold, 1991).  
 
Olfactory dysfunction can arise from a variety of reasons, and aging is the main risk 
factor for olfactory deficits. Further, olfactory deficits have been documented in 
psychiatric diseases like schizophrenia (Atanasova et al., 2008, Moberg et al., 
1997b), anorexia and bullemia nervosa, alcoholic/drug addiction and major 
depression (Atanasova et al., 2008, Moberg et al., 1999, Zucco and Bollini, 2011). 
Olfactory deficits have also been reported for groups of patients with epilepsy (West 
and Doty, 1995), Autism Spectrum Disorders, Attention Deficit Hyperactivity 
Disorder, Obessive-compulsive disorders (Barnett et al., 1999, Segalas et al., 2011), 
multiple sclerosis (Doty et al., 1997a; 2003, Hawkes, 2003, Kovacs, 2004) and 
tumors in the brain and also vascular dementia (Gray et al., 2001). At last, olfactory 
dysfunction is common in neurodegenerative diseases, and will be discussed in 
section 1.3.2. 
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1.3.1.    Olfactory dysfunction in aging 
 
Aging is the most important factor affecting human olfactory function. After the age 
of 80 years above 60 % of individuals have marked dysfunction in olfactory abilities 
(Doty et al., 1984, Murphy et al., 2002, Zanni, 2005). Doty and colleagues suggested 
the decline starts at about 55 years of age, but a more recent study showed that a 
reduction starts as early as at 36 years of age (Doty et al., 1984, Hawkes, 2006). 
The reduced olfactory abilities can be found across several olfactory domains, 
including OI (Doty, 1984, Larsson et al., 2004). The aging effect is demonstrated in 
un-cued OI tests (Larsson and Backman, 1997), and in multiple choice tasks where 
possible odor names are available (Larsson et al., 1999). 
 
Several reasons may cause the olfactory dysfunction seen in aging (Boyce and 
Shone, 2006, Seiberling and Conley, 2004), and effects of aging may occur at all 
levels of the olfactory system. Some of the main factors involved in age-related 
olfactory decline are described below. Firstly, the olfactory epithelium is damaged 
during life by environmental factors like toxins, viruses, bacteria and pollutants. Age-
related deficits caused by such environmental factors have been seen in mice, and 
lead to decreased epithelial thickness, and decreased numbers of olfactory receptors 
and glomeruli (Hinds and McNelly, 1981, Rosli et al., 1999). Secondly, both the fibres 
in the olfactory bulb and the number of olfactory receptors decrease with age (Doty, 
1984). And thirdly, age-related changes in the CNS may affect processing of olfactory 
input in primary and secondary olfactory regions. For instance, the histopathological 
characteristics of AD, neurofibrillarily tangles and amyloid plaques, can be expressed 
in cognitively normal elderly (Davis et al., 1999, Schmitt et al., 2000). Abnormal 
numbers of neurofibrillary tangles have been demonstrated particularly in the 
parahippocampal gyrus and hippocampus of healthy elderly people (Kovacs, 2004, 
Price, 1990). Wilson and colleagues showed that there is an association between OI 
ability and number of tangles in the entorhinal cortex and CA1/subiculum areas of 
the hippocampus in old age, but not in other cortical sites (Wilson et al., 2007). 
Neuroimaging studies show reduced activation in piriform and amygdalar region and 
orbitofrontal cortex in the elderly compared to younger adults (Cerf-Ducastel and 
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Murphy, 2003, Wang et al., 2005). Moreover, general brain atrophy, particularly in 
frontal and temporal lobe, is common in the elderly (Drachman, 2006), and will 
affect the function of these cortical regions. 
 
1.3.2.    Olfactory dysfunction in neurodegeneration 
 
In the mid 1970s Ansari and Johnson, and Waldton, were the first to report that the 
ability to smell is compromised in neurodegenerative diseases (Ansari and Johnson, 
1975, Waldton, 1974). Most neurodegenerative diseases appear to have some 
degree of olfactory dysfunction, though exactly which function is compromised varies 
according to which part of the olfactory system is affected. Moreover, the debut of 
the reduced olfactory ability varies.  
 
The main neurodegenerative diseases where olfactory functions are affected are AD 
(Devanand et al., 2000, Koss et al., 1988, Murphy et al., 1990, Serby et al., 1991), 
Parkinson’s disease (PD) (Haehner et al., 2011) and Huntington’s disease (Moberg 
and Doty, 1997). Reduced olfactory function is also reported in patients with Down’s 
syndrome (Nijjar and Murphy, 2002) and the Lewy Body variant of AD (Olichney et 
al., 2005). A study investigating PD patients showed that a motor-impairment in 
sniffing contributed to the early olfactory deficits in PD (Sobel et al., 2001). The 
results from a meta-analysis including 80 studies of AD and PD patients, reported 
that PD patients are more impaired on low-level perceptual olfactory tasks, whereas 
AD patients are more strongly impaired on higher-order olfactory tasks involving 
specific cognitive processes (Rahayel et al., 2012).  
 
The patterns of neurodegeneration in AD and PD follow different trajectories and 
localizations, and it is not clear if the neuropathological abnormalities occur first in 
peripheral or in the central olfactory systems (Hawkes et al., 1999, Mesholam et al., 
1998, Serby, 1987). According to Braak and colleagues, neurofibrillary tangles occur 
initially in the trans-entorhinal region between the hippocampus and the entorhinal 
cortex in AD (Braak and Braak, 1992). Other findings, though, suggest that the initial 
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pathology appears in peripheral olfactory structures (Kovacs et al., 2001, Price et al., 
1991).  
 
1.3.3.    Olfactory dysfunction in MCI 
 
Studies have shown that patients with MCI perform worse on OI tests and 
discrimination tests compared to healthy controls (Devanand et al., 2000, Eibenstein 
et al., 2005, Wang et al., 2002). Devanand and colleagues reported a significant 
difference in performance on the University of Pensylvannia Smell Identification Test 
(UP-SIT) between non-MCI and aMCI individuals (Devanand et al., 2010). This may 
indicate that the OI-test could have a predictive utility in separating persons with no 
MCI from those with MCI and AD (Devanand et al., 2010). However, other studies 
could not confirm the findings of Devanand et al. Westervelt and colleagues 
investigated OI abilities in different MCI subgroups, and found no differences in OI 
performance between the subgroups using the B-SIT (Westervelt et al., 2008). Two 
longitudinal studies have been conducted to evaluate the usefulness of OI tests as a 
predictor of conversion from MCI to dementia/AD. Devanand and colleagues found 
that OI in patients with MCI predicted AD at follow up (Devanand et al., 2000), but 
Bahar-Fuchs and colleagues failed to find such a statistically significant relationship 
(Bahar-Fuchs et al., 2010). A review by Sun and colleagues published in 2012 
claimed the need for more longitudinal cohort studies to evaluate the usefulness of 
OI tests in predicting MCI to AD conversion (Sun et al., 2012). 
 
Other studies have shown that by combining olfactory testing with 
neuropsychological tests and structural MRI (Devanand et al., 2008, Lojkowska et al., 
2011), the prediction of conversion from MCI to dementia or AD can be improved. 
Lojkowska and colleagues showed that neuropsychological tests combined with OI 
tests improved the prediction of conversion from MCI to dementia (Lojkowska et al., 
2011). They used a set of seven neuropsychological tests, and calculated a sum 
score, Cognitive Functions Index, for a general cognitive performance based on this. 
They also showed that by using the follow up data from two different time points, a 
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reduction in hippocampal volume, in addition to neuropsychological tests and OI 
tests, further increased prediction accuracy (Lojkowska et al., 2011). Devanand and 
colleagues reported that a combination of an OI test, hippocampal and entorhinal 
cortex volume, plus selective reminding test and questionnaire on functioning, 
predict conversion to AD, when patients were followed at six month intervals in a 
three year follow up study (Devanand et al., 2008).  
 
1.3.4.    Olfactory dysfunction in AD 
 
In 1987 Rezek described olfactory deficits as a neurological sign in AD (Rezek, 1987), 
and since then many studies have shown that olfactory impairment is very common 
in AD, and that AD patients perform worse at olfactory tests than both healthy 
controls and MCI patients (Murphy et al., 2003, Steinbach et al., 2010, Westervelt et 
al., 2008). The olfactory dysfunction in AD is reported to affect the detection 
threshold, discrimination, olfactory memory and OI (Arnold et al., 1998, Serby et al., 
1991, Wilson et al., 2007, Wilson et al., 2009). In particular, dysfunction in OI seems 
to occur at a very early stage, and many studies indicate that the first observed odor 
deficit is indeed related to OI, and not the ability to detect odors (Christen-Zaech et 
al., 2003, Hedner et al., 2010, Larsson et al., 2000, Nordin et al., 1997, Rahayel et 
al., 2012, Serby et al., 1991). The deficits in olfactory function may occur prior to the 
advent of typical cognitive deficits and behavioural disturbances in AD (Bacon et al., 
1998, Devanand et al., 2000, Graves et al., 1999). 
  
It has been widely debated whether the earliest pathological changes in AD related 
to olfactory dysfunction occur in the olfactory epithelium, bulb, or more central MTL 
and/or other higher order structures in the brain. The two major theories that 
attempt to explain the olfactory loss in AD are the olfactory vector theory, and the 
degenerative theory. The olfactory vector theory is based on environmental agents, 
which are considered to enter the brain via the olfactory mucosa, and subsequently 
cause damage to the neuronal cells (Doty, 2008). Based on this theory the damaging 
toxins do not mainly cause damage to the epithelium, but also use this route to 
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reach the brain (Youngentob et al., 2001). The olfactory system has the shortest 
pathway from a sensory organ (in this case epithelium) to the MTL, measured in the 
number of synapses. However, in general the olfactory vector theory lacks evidence 
and support. 
 
The degenerative theory of olfactory dysfunction in AD is based on the earliest 
pathological changes being found in the MTL (Braak and Braak, 1992, Devanand et 
al., 2012). Early neurodegeneration in entorhinal cortex and hippocampus will lead to 
specific impairment of functions relying heavily on these structures. Testing of such 
functions will hence be particularly sensitive indicators of the earliest stages of the 
disease. According to this theory, olfactory tasks with greater cognitive components 
should challenge the system most effectively, and thus have greatest sensitivity for 
detection of AD (Iqbal, 2001). 
 
Abnormal changes have been observed in the olfactory epithelium in patients with 
probable AD (Tabaton et al., 1991, Talamo et al., 1989). Amyloid-beta and paired 
helical filament -tau occur early and severely in brain regions sub serving olfaction, 
and also in the olfactory epithelium (Arnold et al., 2010). Amyloid and neurofibrillary 
tangles are also found in the olfactory bulbs in AD (Kovacs et al., 2001). In addition, 
neurofibrillary tangles are observed in the anterior olfactory nucleus of some AD 
patients even before neurodegenerative changes can be seen in entorhinal cortex 
(Kovacs et al. 2001). Thomann et al. 2009 carried out MRI studies, and showed a 
reduction in size of the olfactory bulb and tract in the early stages of AD (Thomann 
et al., 2009a, Thomann et al., 2009b). Olfactory bulbs are reduced in size in persons 
with olfactory loss compared to healthy people (Haehner et al., 2008). This is also 
seen in elderly compared to younger people who do not complain of any loss of 
olfactory sense (Yousem et al., 1998), as well as in patients with AD (Thomann et 
al., 2009b).  
 
Few studies have investigated the olfactory deficits in patients with AD using imaging 
methods. However, recent new studies using functional magnetic resonance imaging 
(fMRI), PET and structural MRI have been published (Bahar-Fuchs et al., 2010, 
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Forster et al., 2010, Kareken et al., 2001, Murphy et al., 2003, Wang et al., 2010). 
One study demonstrated fMRI to be sensitive to changes in olfactory function due to 
AD. Blood oxygen level-dependent (BOLD) signals in the primary olfactory cortex, 
hippocampus, and insula regions were markedly reduced in AD patients compared to 
healthy control subjects of similar age (Wang et al., 2010). A PET study reported a 
positive association between OI scores and odor-induced activity in the right piriform 
cortex, though this was in a combined group of AD patients and healthy controls, 
and the sample size was small (8 patients and 8 controls) (Kareken et al., 2001). In a 
Fludeoxyglucose, 18F (FDG) PET study of different olfactory domains (OI, odor 
discrimination and threshold) performed in patients with early AD, the OI scores 
correlated with the normalized FDG uptake in clusters with peaks in the right 
superior parietal lobe, fusiform gyrus, inferior frontal gyrus and preuncus (Forster et 
al., 2010). Another study used Pittsburg Compound B (PIB) PET-scanning, and an OI 
task in 24 persons with aMCI, 20 AD patients and 19 controls. The OI scores and PiB 
binding differentiated aMCI and controls clearly, but no differences in OI scores 
between aMCI patients who where PIB-positive and those who where PiB-negative 
were found (Bahar-Fuchs et al., 2010).  
 
The role of olfactory event-related potentials (oERPs) is considered useful in the 
diagnosis of AD (Morgan and Murphy, 2002). However the results from research 
studies using oERPs generated in the medial temporal cortex is contradictory 
(Kettenmann et al., 1997). In one study about half of the patients with AD or MCI 
had a normal response to olfactory stimulation (Peters et al., 2003), whereas in 
another study, changes in oERPs latency measures resulted in a 100 % correct 
classification of AD (Morgan and Murphy, 2002).  
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2.0. Methods 
 
Methods used to investigate the aims of the thesis were new advanced MRI-based 
techniques; fMRI (Paper III) and structural MRI (Paper IV), in combination with 
psychophysical tests (Paper I, II, and IV).  
 
 
 
Figure 3. A schematic representation of the methods used in the thesis. 
 
 
2.1.   Psychophysical tests 
 
Psychophysical tests are standardized methods to assess olfactory function in 
patients with olfactory loss, and may help us obtain objective evaluation of the 
olfactory performance. Various types of test have been developed for use in different 
cultural regions to assess domains of olfactory function (Eibenstein et al., 2005).  
 
OI tests can be divided into three groups based on how they are organized: 1) 
spontaneous or un-cued OI tests, 2) yes/no identification tests and 3) multiple choice 
tests (Hawkes, 2009). In naming tests no alternatives are given, while for the yes/no 
identification tests the subjects are asked questions like "does this smell like a 
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banana?". The multiple choice tests are the most common, and consist of a number 
of commonly known odors that the participants are instructed to name after being 
presented with alternatives to choose between (i.e. forced multiple choice; usually 
with four odors). The multiple choice tests are often based on "scratch and sniff" 
techniques. The University of Pennsylvania Smell Identification Test (UPSIT) is one of 
the most widely used smell tests in the world and is produced in the USA by Sensonic 
Inc. (Doty et al., 1984). The UPSIT consists of 40 "scratch and sniff" odorants. B-SIT 
(also known as CC-SIT) is a short validated version of the UPSIT, originally made for 
self-evaluation of olfactory function (Doty et al., 1996, Sensonic Inc., Haddon 
Heights, USA). B-SIT is a 12-item, four choice, "scratch and sniff" test, and the 
odorants are placed on strips embedded in 10-50 μm ureaformaldehyde polymer 
microcapsules, and released when the strips are scratched with a special pencil. The 
odorants included in the test are cinnamon, turpentine, lemon, smoke, chocolate, 
rose, paint thinner, banana, pineapple, gasoline, soap and onion. Each correctly 
identified odor receives one point, thus giving a possible score of 0-12 points with 
the B-SIT.  
 
Sniffin Sticks Test is a European product by the Burghart Company, and is a battery 
including the Sniffin Sticks Odor Identification Test (SSIT), Threshold test and the 
Sniffin Sticks Discrimination Test (SSDT) (Hummel et al., 1997, Kobal et al., 1996). 
Also a 12-item screening version has been developed (SSSIT) (Hummel et al., 2001). 
Sniffin Sticks are felt-tip pens filled with an odorant, where removal of the caps 
releases the odors. The pen is held approximately two centimetres in front of the 
nostrils. SSIT contains 16 single sticks and a multiple choice task, where a list of four 
descriptors is presented. The sticks contain familiar odors such as orange, leather, 
cinnamon, peppermint, banana, lemon, liquorice, garlic, coffee, apple, clove, 
pineapple, rose, aniseed and fish. For the SSIT part of the test, subjects need to 
select one of the four items presented both in writing and orally, which best describe 
the odor. The SSDT consists of 16 triplets, where two pens have the same smell, 
while one of the three pens contains a different odor. The subjects are asked to 
identify the pen with the different odor, and are blindfolded during the task because 
the pens are color-coded. In SSIT and SSDT, correctly-identified odors receive one 
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point, giving a possible score range of 0-16 for both SSIT and SSDT. The B-SIT and 
SSIT are commercial olfactory screening tools developed for use in different 
countries (Doty et al., 1996, Hummel et al., 1997, Kobal et al., 1996), but are not 
successfully validated cross-culturally (Kobal et al., 1996, Hummel et al., 1997, 
Hummel et al., 2007). Therefore many local variants have been developed. The B-
SIT test has been translated into various languages (Swedish, Danish, Dutch, 
English, German, Greek, Chinese and Turkish), and in some cases odor-changed 
because they vary across cultures (Sensonics.com). For the SSIT, many local variants 
have been developed (England, Australia, Greece, Italy, Holland, Sri Lanka, Brazil 
and Taiwan) (Konstantinidis et al., 2008, Neumann et al., 2012, Shu and Yuan, 2008, 
Yuan et al., 2010). The local variants produced have been modified in a manner 
which includes translation, and in some cases the odor-items changed and/or 
different distractors included. A ten-item version of the B-SIT was developed, 
specially design to evaluate AD patients, called B-SIT A (Tabert et al., 2005). 
Furthermore, "Taste strips" from the Burghart Company (Burghart Messetechnik 
GmbH, Wedel, Germany) constitute a validated taste test (Landis et al., 2009), 
where subjects have to identify one taste at a time from a list of five descriptors, i.e. 
sweet, sour, salty, bitter and "nothing to taste" (multiple five-choice). 
 
  
 
Figure 4. The psychophysical tests for measuring OI used in this thesis were SSIT 
(right side) in study III and IV and B-SIT (left side) in study I, II, III and IV.  
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2.2.   Magnetic Resonance Imaging (MRI) 
 
MRI is often divided into structural MRI and fMRI. MRI uses strong magnetic fields 
and radio waves to create images of biological tissue. The static magnetic field 
created by an MRI scanner is expressed in units of Tesla. The magnetic field inside 
the scanner affects the properties of nuclei of certain atoms with uneven mass 
number, and a significant magnetic moment. MRI is based on signals from hydrogen 
nuclei which are abundant in fat and water in the human body. Nerve cells, for 
example, are relatively rich in water, whereas the fatty coating around the nerve 
fibers and cells, called myelin, has less. 
 
A hydrogen nucleus consists of a single proton that spins around its own axis. The 
spinning inducing a magnetic field with a certain direction and size, called the 
magnetic moment, which induces the type of signal that is detected by MRI 
scanners. When a person is inside the powerful magnetic field of the scanner, the 
average magnetic moment of many protons becomes aligned parallel with the 
direction of the field (Bo), in order to maintain a low energy state, or equilibrium. 
During image acquisition, a radiofrequency (RF) pulse is turned on, the energy of the 
RF pulse is absorbed by the hydrogen nuclei, and the total amount of magnetic 
moment is flipped into the transverse plane. When the RF pulse is turned off, the 
spins of the protons return to their low energy state or equilibrium, and the 
magnetization becomes re-aligned with static magnetic field. Several relaxation 
processes occur (e.g. T1 recovery, T2 decay) and at different rates in different types 
of tissue, and this RF signal can be measured with receiver coils in the MRI-scanner 
and constitutes the basis of the different types of MR contrasts. 
 
2.2.1.    Structural MRI 
 
Measuring atrophy in AD with structural MRI is a powerful biomarker (Vemuri and 
Jack, 2010), and structural MRI was used to obtain volumetric measurements of 
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brain structures in Paper IV. Whole brain structural MRI scans were acquired on a 
Siemens 3.0 Tesla Trio MRI-scanner and a 12 channel head coil at St.Olavs Hospital. 
A T1-weighted 3D-scan was obtained with sagittal acquisition and repetition time 
(TR) =2300 ms and echo time (TE) =2.94 ms and 256 scans. The structural volume 
data were analyzed using NeuroQuant (CorTechs Labs Inc., CA, USA) which performs 
an anatomical segmentation and volumetric measurement of brain structures 
(http://www.cortechs.net/index.php) (Brewer, 2009). Several structures were 
estimated, but in the present context only the brain structures most relevant for AD, 
and considered to be involved in olfaction were included; total volume of hemispheric 
white matter, cortical grey matter, thalamus, hippocampus, amygdala, and the 
ventricular space. The volume of each structure was calculated as a percentage of 
the overall intracranial volume.  
 
2.2.2.    Functional MRI 
 
fMRI is a non-invasive method for indirectly observing neural activity, based on 
hemodynamic responses to neural activity. The principle of fMRI imaging is to take a 
series of images of the brain in quick succession and statistically analyze the images 
for differences among them. Ogawa and his colleagues demonstrated that gradient 
echo (i.e.T2*-weighted) MRI signals are sensitive to the level of blood oxygenation in 
the brain, and this phenomena was called blood oxygen level-dependent (BOLD) 
contrast (Ogawa et al., 1990). 
 
The physiological basis of the method depends on the relationship between neuronal 
and vascular processing. The activated neuronal cells need energy (in the form of 
ATP), from oxidative metabolism, which requires oxygen provided by oxygenated 
hemoglobin in the red blood cells in the surrounding capillaries. The hemoglobin has 
varying magnetic susceptibility depending on the presence of the oxygen. Without 
attached oxygen, the resulting deoxygenated hemoglobin is paramagnetic, while 
oxygenated hemoglobin is diamagnetic (See figure 5, A) (Ogawa et al., 1990). 
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Figure 5. A. Illustration of the difference in concentration of deoxygenated 
hemoglobin (grey) and oxygenated hemoglobin (red) in a resting and activated state. 
B. The Hemodynamic Response Function (HRF). 
 
When neural activity increases, the blood flow will also increase within 1-2 seconds 
after the beginning of activity, and reaches its maximum amplitude after about 4-6 
seconds. BOLD fMRI thus measures a correlate of neural activity, the hemodynamic 
response, HRF, see Figure 5, B. The HRF is the change in MRI signal on T2* images 
following local neuronal activity. The hemodynamic response results from a decrease 
in the amount of deoxygenated hemoglobin present within a voxel (Huettel, 2004). 
After the HRF, a poststimulus undershoot occurs where the BOLD signal is below the 
baseline (see Figure 5, B). The cause of this undershoot is still a matter of debate 
(Buxton, 2012), but may be a result of a reduced arteriolar and capillary blood flow, 
and increased venous blood volume (Huettel, 2004). The exact relationship between 
the hemodynamic responses and the underlying neural activity remains to be 
elucidated (Attwell and Iadecola, 2002). However, it has been shown that the BOLD 
signal reflects neural activity and in particular local synaptic processing (Logothetis et 
al., 2001, Viswanathan and Freeman, 2007).  
 
In order to capture changes in the BOLD signal, fast imaging sequences like Echo 
Plannar Imaging (EPI) are necessary (Poustchi-Amin et al., 2001). However, the use 
of EPI has certain costs. Its main limitation is the magnetic field inhomogeneity in 
regions of the brain close to bone and air-filled sinuses, i.e. susceptibility artefact 
(Gorno-Tempini et al., 2002, Ojemann et al., 1997). In particular, this is a problem 
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for imaging the MTL and the areas involved in olfactory function, and signal loss may 
appear for these regions. In addition, the BOLD signal from the MTL and other deep 
brain structures is lower due to coil effects (Kaza et al., 2011). 
 
2.2.3.    Olfactometer 
 
fMRI provides a way of observing the active brain while participants solve different 
cognitive tasks or are exposed to specific stimuli (Krause et al., 2006). MRI can be 
used to produce activation maps showing which parts of the brain are involved in a 
particular mental process. For olfactory functional studies, MRI-compatible systems 
to deliver odors to the subjects are required. For this project two olfactometers were 
built, one manually-controlled olfactometer used in Paper III, and one automatically-
controlled olfactometer used in an fMRI experiment not included in this thesis. 
 
The manually-controlled olfactometer consisted of three glass chambers, one filled 
with water and two with odorants, and a mechanical switch box to regulate airflow 
through the individual chambers. The olfactometer was built by the Medical Technical 
Department at St. Olav’s Hospital. The design allowed administration of multiple 
odors by replacing the glass chambers filled with odorants. This was possible due to 
the long odor-free breaks in the fMRI-paradigm. Medical air flowing at a rate of 15 
l/min was passed through the olfactometer, allowing the odors to be released from 
the liquids. From the chambers odors were conveyed via Teflon tubing to a nasal 
mask (Respironics, ScanMed AS, Norway). Task instructions with regard to odor 
presentation, duration and switching were coordinated by E-Prime (Psychology 
Software Tools, Pennsylvanina, USA), and displayed to the experimenter on an LCD 
screen in the scanner room. 
 
The MR-compatible automatically-controlled olfactometer was designed by an 
engineer at the Norwegian University of Science and Technology (NTNU). 
Background information from other studies and laboratories for building inexpensive 
MR-compatible olfactometers was compiled by members of the fMRI group and a 
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sketch of the olfactometer served as a basis for the engineer’s design. This 
olfactometer consisted of 14 glass chambers for liquids, and from these chambers 
odors were conveyed via Teflon tubing to a nasal mask (Respironics, ScanMed, AS, 
Norway). The odor presentation sequence, i.e. timing, duration and order of 
presentation was programmed with the olfactometer. The olfactometer is started by 
the experimenter using a remote control exactly at the time of initation of task 
instructions and fMRI scanning.  
 
In order to remove odors and also ensure the movement of air past the subject’s 
nostrils, a hole at the superior end of the mask was made and connected to the 
hospital`s gas evacuation system. All tubings were made of very low absorbent 
material (Teflon Fluorinated Ethylene Propylene), to avoid absorption of odor 
molecules into the tubes (Vigouroux et al., 2005). Task instructions concerning the 
operation of the automatically-controlled olfactometer by the experimenter were 
used in E-Prime (Psychology Software Tools, Pennsylvanina, USA). The experimenter 
viewed the task instructions on the computer-screen in the scanner room.  
Responses from volunteers were recorded using response buttons (NordicNeuroLab 
AS, Bergen, Norway). Both button use and reaction times were logged in E-prime. 
The subjects were told not to sniff, but to breathe regularly throughout the entire 
experiment, and to let the air pass over and into the nose. Each odorant was 
presented for 10.4 seconds to ensure that at least one breathing cycle was 
completed within the stimulus duration. A behavioural experiment was carried out to 
measure respiration rate and depth of respiration during presentation of identified 
and non-identified odors. Respiration rate and depth were measured with a 
respiration-belt connected to Powerlab (AD Instruments Pty Ltd. Unit 13, 22 
Lexington Drive, Bella Vista, NSW 2153, Australia). 
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Figure 6.  Images of the two olfactometers produced for this project. The manually-
controlled olfactometer used in study III is shown in the upper image. The 
automatically-controlled olfactometer is shown in the lower image and was used in 
an fMRI experiment not included in this thesis. 
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3.0. Aims 
 
This thesis had three main aims. The first aim was to investigate the feasibility of 
using commercially available olfactory screening tools in Norwegian cohorts (B-SIT, 
as well as a modified version of B-SIT, and SSIT). The second aim was to explore the 
neuronal correlates of OI in the healthy human brain. The third aim was to identify 
the anatomical brain substrates underlying OI abilities in patients with aMCI and 
early dementia in AD. 
 
Four studies were performed, each targeting different aspects of the aims. 
 
1. Are B-SIT and SSIT suitable tests for separating patients with AD, early 
dementia in AD, and aMCI from healthy controls in Norwegian cohorts, and 
could a modified version of B-SIT by introduction of a placebo be a more 
appropriate approach to study OI, in particular in a general population?  
(Study I, II and IV) 
 
2. Which human brain structures engender successful OI?  
(Study III and IV) 
 
3. How are the OI abilities in patients with aMCI and early dementia in AD 
related to volumes of brain structures, and performance on cognitive tests? 
(Study IV) 
 
 
 
 
 
 
 
 
 42 
4.0. Summary of papers 
 
4.1.  Paper I 
 
Use of the Brief Smell Identification Test for olfactory deficits in a Norwegian 
population with Alzheimer’s disease. 
 
The purpose of this paper was to further our knowledge of the the validity of the B-
SIT in distinguishing patients with AD from healthy controls in a Norwegian cohort. 
 
The study included 39 patients with a diagnosis of AD according to the NINCDS-
ADRDA criteria, and 52 gender and age-matched controls, healthy relative to their 
age. The ability to identify odors was tested with B-SIT and a non-standardized OI-
task (freshly ground coffee).  
 
The results from the study showed a highly significant difference in OI measured by 
B-SIT between patients with AD diagnosis and controls. The results showed an 
optimal cut-off point of ≥8 of B-SIT score for the AD patients group, with sensitivity 
of 79 % and specificity of 92 % for distinguishing between AD and healthy controls. 
Turpentine was the odor with the lowest score for any of the items in the test, 
correctly identified by only 21.2 % of the controls and 23.1 % of the AD patients 
(chance level). 
 
To conclude, the B-SIT test appears to be well-suited for use in a Norwegian cohort. 
This study showed that the B-SIT test could detect deficits in OI among patients with 
AD and healthy controls, in a Norwegian setting. 
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4.2.  Paper II 
 
Modification of the Brief Smell Identification Test by introduction of a placebo. 
 
As awareness increases among the population that reductions in olfaction are 
associated with neurodegenerative diseases, it may be necessary to introduce an 
odourless placebo test, so the subjects do not actually know whether they cannot 
smell, or whether there is nothing to smell. Previous studies showed turpentine to be 
an odor not generally recognized in Norway, were only 21 % of the healthy controls 
(Paper I), and 37.5 % of the healthy young subjects (Paper III) identified turpentine.  
 
Seventy-one elderly individuals, healthy for their age, were recruited from a sub-
study of the third Nord-Trøndelag Health Study (HUNT3). Participants were warned 
that there might be nothing to smell prior to olfactory testing. They were blindfolded 
before being given the modified B-SIT where one item (turpentine) had been 
replaced with a placebo, and one odor alternative answer to three other items was 
replaced by the alternative "none/other" (actual odor unchanged). 
 
The replacement of the item "turpentine" with a placebo resulted in a significantly 
improved score for the item (53.5 %) compared to a previous study (p<0.0005) 
(Paper I). There was no overall difference in the median or mean score achieved by 
the cohort compared to results obtained previously using the conventional B-SIT. 
 
To conclude, it is possible to introduce the concept that there may be "nothing to 
smell" to the B-SIT without compromising the test for healthy control individuals. 
Introduction of a placebo and the alternatives "none/other" seem to be a more 
appropriate approach for olfactory testing in healthy subjects and patients with 
neurodegenerative diseases. 
 
 
 44 
4.3.  Paper III 
 
The human brain representation of odor identification. 
 
The utility of OI tests as a clinical tool depends on a better understanding of the 
neuronal processes underlying OI. The main aim of the present study was to directly 
compare the neuronal correlates to identified odors versus non-identified odors in the 
human brain to understand the neurobiology of OI, as this is increasingly being used 
as a sensitive marker for neurodegenerative diseases such as AD. 
 
We included 17 females with normal olfactory function in the study. All participants 
underwent an fMRI experiment with post-scanning assessment of spontaneous un-
cued OI. Post scan assessment also included testing with B-SIT and SSIT. Analysis 
was done to compare spontaneously identified versus non-identified odors at a whole 
brain level, as well as in ROIs (anatomical and functional) in the medial temporal 
lobe. Parameter estimate values and BOLD signal curves were obtained from the 
functional ROI`s in central olfactory structures. The number of activated voxels and 
maximum parameter estimate values were obtained from anatomical ROIs in the 
hippocampus and the entorhinal cortex. 
 
At the whole brain level, correct OI gave rise to increased activity in left entorhinal 
cortex, and secondary olfactory structures including orbitofrontal cortex. In 
entorhinal cortex and hippocampus, the BOLD signal increased specifically in 
response to identified odors and decreased for non-identified odors. Episodic as well 
as semantic memory systems appeared to support OI. 
 
The study demonstrated clearly that brain activity in relation to spontaneous OI is 
distinct from non-identified odors, and also differs from activity during passive 
smelling. The results support a specific role for entorhinal cortex and hippocampus in 
OI. 
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4.4. Paper IV 
Odor identification and brain structural MRI volume in MCI and early dementia in 
Alzheimer’s disease. 
 
In Paper I we found that a minority of the patients with AD still had a relatively intact 
OI function, although the majority of these patients had reduced OI function. A 
prospective follow-up study of patients with a diagnosis of aMCI or early dementia in 
AD was designed, with the aim to understand the anatomical substrates underlying 
deficits in OI performance. Other aims were to explore the relationship between OI 
function and volumetric and cognitive measures in healthy elderly individuals, 
compared to patients with aMCI and early dementia in AD with intact and reduced OI 
abilities. 
 
12 patients with a diagnosis of aMCI, and six with early dementia in AD were 
included from the Memory Clinic at St. Olavs Hospital. In addition, 30 controls were 
included from the Trondheim area. All participants were evaluated with three 
psychophysical tests; B-SIT, SSIT and SSDT. In addition, a taste test was used as 
well as cognitive tests. Brain structural volume data was recorded from all 
participants and blood samples were collected for ApoE-genotyping. The overall 
group of patients was divided into two subgroups based on their OI abilities, 
according to the performance on B-SIT and SSIT. 
 
The baseline B-SIT score did not differentiate patients with MCI from those with 
early AD at baseline (p>0.4), but prospectively a significant difference in B-SIT 
scores at baseline was found between patients with stable MCI 6-8 months later, and 
those that had progressed to an early stage of dementia in AD (t-test, p =0.037). 
Hippocampal volume was significantly reduced in the impaired OI group compared to 
the intact OI group, when subgroups were divided based on both OI-tests used in 
this study. To conclude, the results suggest that patients with aMCI and early 
dementia in AD can be subgrouped into "intact" and "impaired" OI groups based on 
simple olfactory tests, and that sub divisions help distinguish those with a more 
advanced development of AD. 
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5.0. Discussion 
 
The overall aim of this doctoral thesis was to investigate the feasibility of using 
commercial olfactory screening tools in Norwegian cohorts, and to explore the 
neuronal correlates and anatomical brain substrates of OI in healthy young and older 
adults, and patients with aMCI and early dementia in AD. 
 
5.1.  The use of olfactory screening tools in Norway 
 
In the clinic OI tests are increasingly used in addition to neuropsychological testing, 
for the diagnosis of neurodegenerative diseases like AD and PD (Wolfenberger, 
1999). The present work (Study I, II and IV) shows that B-SIT and SSIT both 
demonstrated a highly significant difference in olfactory performance between 
patients with an AD diagnosis and controls, early dementia in AD and controls, and 
aMCI compared to controls. Furthermore, both B-SIT and SSIT had high sensitivity 
(SS) and specificity (SP) for use in Norwegian cohorts (Paper I, II and IV). B-SIT 
showed even greater discrimination between AD patients and controls than a 
previous study (Suzuki et al., 2004). SSIT showed a moderate sensitivity compared 
to another study using the same cut-off (cut-off ≤8, SS 96.4 %, SP 78.1 %) 
(Miyamoto et al., 2010), however the SS and SP are more or less similar to what 
others report for SSIT in other cohorts (Boesveldt et al., 2008, Konstantinidis et al., 
2008, Shu and Yuan, 2008, Yuan et al., 2010). This verifies that there is comparable 
SS and SP for both B-SIT and SSIT in Norway, as found in other countries worldwide. 
 
Norms have been developed both for B-SIT (Doty, 2001) and SSIT (Hummel et al., 
2007), for distinguishing between subjects with normal and abnormal OI function. 
Still, there is no consensus for a specific cut-off value that distinguishes AD patients 
with impaired OI function from healthy age and sex-matched subjects. Therefore, we 
used cut-off scores based on results from previous studies in AD and healthy elderly 
people, with B-SIT (Westervelt et al., 2007) and SSIT (Boesveldt et al., 2008) (Paper 
IV). In paper IV, using a cut-off of 7, B-SIT showed SS of 86 % and SP of 82 %, 
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while SSIT, using a cut-off of 8, also showed high SS and SP (83 % and 82 %, 
respectively). Since a cut-off for B-SIT of 7 was used (7 items of total 12, is 58 %), 
the cut off for SSIT should perhaps have been 9 (9 items of total 16, giving 56 %) 
for the cut-offs to be similar. In fact the accuracy of SSIT scarcely changed when the 
cut-off was raised to 9 of 16 items, giving an SS of 83 % and SP of 82 %. Results 
from the present work show that there are weak effects on SS and SP depending on 
where the cut-off is set. 
 
The combined group of patients with aMCI and early dementia in AD showed a mean 
OI score of 6.6 points for B-SIT (Paper IV), while the AD patients showed a mean 
score of 6 points (Paper I). This latter result is in line with the B-SIT score for AD 
patients in another study (Westervelt et al., 2008), but a higher score than reported 
in a Japanese population (Suzuki et al., 2004). There was no large age difference 
between the patients with AD in our study I compared to Suzuki et al., but the mean 
score on MMSE (19.6) was lower in Suzuki et al. compared to the AD patients in 
Study I (mean score on MMSE 23). More severely affected cognitive abilities may 
have been a contributing factor leading to lower B-SIT scores. 
 
Compared to previous studies of MCI patients (Tabert et al., 2005, Westervelt et al., 
2008, Wang et al., 2002), the B-SIT score in Paper IV was rather low. In a study 
based on 10 odors, a mean score 9.6 was found in a group of MCI patients (Tabert 
et al., 2005). The MCI patients in this study had a mean score on MMSE of 27.3, 
compared to a mean score of 25.5 on MMSE in our study IV, which may explain the 
better performance on B-SIT for the patients in Tabert et al. Since both aMCI 
patients and patients with an early stage of dementia in AD were included, the mean 
performance in Paper IV may be lower than in an exclusive MCI group as used in the 
other studies (Tabert et al., 2005, Wang et al., 2002, Westervelt et al., 2008). Many 
of the patients in Study IV converted to AD within the 6-18 months follow up. 
However, when separating patients with aMCI at baseline (n=12), from the patients 
with early dementia in AD (Study IV), the mean score on B-SIT was 6.9 in the pure 
aMCI group, which is in line with previous studies (Wang et al., 2002, Westervelt et 
al., 2008). 
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In Paper IV we subdivided the patients according to B-SIT and SSIT scores into 
"intact" or "impaired" OI function. More patients were considered "intact" by SSIT 
than by B-SIT (Paper IV). However, everyone considered "intact" by B-SIT was also 
considered so according to SSIT scores. There was a strong positive correlation 
between B-SIT and SSIT scores, both in patients with early AD and aMCI, and in the 
control group (Paper IV). Another study comparing B-SIT, Sniffin Sticks (including 
the SSIT) and the European Test of Olfactory Capabilities (ETOC), found a 
correspondence between all the tests. All the tests separated subjects with normal 
and abnormal olfactory function significantly (Koskinen et al., 2004). However, when 
olfactory function was categorized by Sniffin Sticks (entire test), 36 out of 48 
categorized as anosmic, hyposmic or without loss of smell based on B-SIT, where 
similar to those achieved by Sniffin Sticks (Koskinen et al., 2004). This may be 
caused by some patients being on the border between what can be considered 
"intact" and "impaired" OI according to a given test in both studies. 
 
OI tests were found to have comparable ability to distinguish between healthy 
controls and patients with aMCI or AD in Norway as in other countries, and therefore 
seem to be well adapted for use here. Yet some restrictions were found both for 
SSIT and B-SIT. Correct identification is possible only if the individuals have had 
previous experience of the odor presented, and using relevant tests adapted to the 
culture of the study population is important. Neumann and colleagues reported a lack 
of familiarity in the British cohort for the item turpentine (Neumann et al., 2012). 
This is in line with our findings, for SSIT in study IV, and B-SIT in all of our studies. 
Turpentine was the odor-item most seldom identified in controls in all our studies 
using B-SIT, (21.2 %, 37.5 %, 25 % correctly identified in Paper I, Paper III and 
Paper IV, respectively). In paper I and IV the patients were older, which may explain 
the slightly better performance in the young subjects in Paper III, compared to the 
older groups in Papers I and IV.  
 
In Paper II we replaced turpentine with a placebo, which resulted in a significantly 
improved score for the item (53.3%) compared to previous study, Paper I 
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(p<0.0005). In the development of the B-SIT version (or CC-SIT), the most familiar 
odors in several countries were selected from UP-SIT (Doty et al., 1996). In a 
Swedish population (n= 96), a study item analysis on the difficulty of the UP-SIT 
items was performed (Doty et al., 1996, Sandmark et al., 1989). In Sweden most of 
the UP-SIT items were correctly identified by 90 % or more of the population, 
including the item turpentine, which was correctly identified by 88.68 %. The 
recognition pf turpentine in Sweden was thus much better than in our Norwegian 
cohorts. Turpentine seems not to be a common everyday odor among Norwegians. 
Despite the modification of item two (Study II), it was still the item with the lowest 
number of correct answers. However, we believe this may caused by the faint odor 
that is carried by the paper in new B-SIT booklets. 
 
Turpentine is also an odor item in SSIT, but in this test turpentine was correctly 
identified by 67.4 % of the healthy controls (Paper IV). The distractors of turpentine 
in SSIT were mustard (0%), rubber (13 %) and menthol (19.6 % answered this). 
The distractors for turpentine in B-SIT were soap, dog and black pepper. The other 
differences observed between B-SIT and SSIT were based on how the odors are 
presented. The odor presentation in B-SIT may depend on how the experimenter 
scratches the booklet, while in SSIT the odors are released when removing the cap 
of the pen, and the latter presentation is thus similar each time. Olfactory 
performance may therefore be affected by the alternatives in a given test, odor 
familiarity, and how the odors are released in the test.  
 
OI tests appear to have several benefits as a screening tool in patients with AD. 
Firstly, the administration of the tests is simple and easy to perform. Secondly, OI 
tests take only a few minutes. The latter is especially important for patients with AD 
who have a reduced time window of short-term memory. The alternatives in OI tests 
for each odor were given orally twice; before smelling the odor and afterwords, for 
both patients and controls. However, the AD or MCI patients reduced memory 
function could have affected their choice, and they may have more often chosen 
from the two last alternatives. However, the results from Paper I demonstrated that 
patients with AD did not choose from the last two test alternatives more often than 
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the first two. Thirdly, OI tests are inexpensive, and this is important because of cost-
constraints in clinical practice. Another important aspect is that the use of 
standardized tests e.g. SSIT and BSIT, gives the opportunity of comparing results 
with previous research across countries. We are in collaboration with the company 
producing B-SIT (Sensonics Company) to develop a Norwegian version based on the 
present work (work in progress). The B-SIT was claimed to be a self-administrative 
test by the company when first produced (Doty et al., 1996). However, in my opinion 
this is not an optimal way for testing patients with neurodegenerative diseases such 
as AD. On the other hand, I believe that OI tests are well-suited for use both by 
general practitioners and in specialized clinics.  
 
5.1.1.   Ethical considerations regarding the use of OI tests as 
screening tools for neurodegenerative disease 
 
Paper II highlights the ethical challenges connected with the use of olfactory testing 
for screening in a general population. Since olfactory impairments are common in the 
elderly, and might predict cognitive decline and AD, such information might 
potentially spread uneasiness in the elderly population and their relatives. Individuals 
who believe that they or their loved ones have a poor sense of smell may equate this 
with insipient dementia. In Paper II, we investigated a modified B-SIT version by 
introduction of a placebo to see if this could be a more appropriate approach for 
testing olfaction in large samples.  
 
Introducing the alternative "none/other" to an odorless placebo has several benefits. 
Firstly, this modification allows the experimenter to introduce the concept that there 
might be nothing to smell to the test-subject. Secondly, such a modification reduces 
expectation that every odor task will be a true odor. Thirdly, this allowed us to 
remove the item turpentine identified by very few Norwegians in study I. We believe 
that a psychophysical test like B-SIT should ideally provide information and answers 
for the tester rather than for the test subject, and an olfactory test where the 
subjects have no particular expectation of odors would hence be preferable.  
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An increasing number of healthy controls will probably be included in OI research in 
coming years due to the focus on olfaction and AD. The volunteers in study II were 
not participating in a research study involving an increased risk or presence of a 
neurodegenerative disease. Rather, they wanted to contribute to a sub-study of 
HUNT3. In addition, there are no treatment options for MCI/AD, and early detection 
is not associated with better prognosis at present. Based on our findings the 
modified version in Paper II may be a more acceptable approach to olfactory testing.  
 
5.2. Approaches to successful OI 
 
Previous findings claim that neuronal correlates of odor processing are task-
dependent (Dade et al., 1998, Savic et al., 2000, Savic, 2002). The analysis of whole 
brain activation during passive smelling, showed bilateral activation in piriform cortex 
and amygdala in healthy young subjects (Study III). Activation was also observed in 
orbitofrontal cortex and thalamus bilaterally, and right cingulate gyrus and left insula. 
Many of these structures are reported to be olfactory core regions (Dade et al., 1998, 
Savic, 2002, Savic et al., 2000). In addition, smaller clusters were reported in for 
example cerebellum, superior frontal gyrus, precentral gyrus, paracingulate gyrus 
and right putamen. In the present work, the OI analysis reported activation in some 
of the same structures as in passive smelling, including both primary and secondary 
olfactory areas, as well as in a number of other cortical regions. However the precise 
localization of the activity within these regions varied. Significantly increased activity 
was found bilaterally in orbitofrontal cortex, thalamus, insula, putamen, visual cortex 
(VA BA17), premotor cortex, secondary somatosensory cortex and cerebellum. Right 
cingulate gyrus and right pallidum were also more active for identified odors. In 
addition, many different structures were activated in the left hemisphere, see Paper 
III. The finding that OI activated unique regions as well as regions found in passive 
smelling, supports the hypothesis that olfactory information is processed by a 
network of brain regions, and that the nature of the olfactory task determines which 
additional brain regions are recruited (Dade et al., 1998, Savic et al., 2000, Savic, 
2002). 
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The results from Paper III demonstrated an increased activity in left entorhinal 
cortex in the within-subject whole brain analysis. In addition, significant differences 
in the parameter estimate values between identified and non-identified odors in the 
functional entorhinal ROI, as well as the very high number of activated voxels and 
maximum parameter estimate value in the anatomical entorhinal region of interest 
(ROI) were found. This is the first imaging study of OI to report increased activation 
in entorhinal cortex (Kareken et al., 2003, Savic et al., 2000, Suzuki et al., 2001). 
This may be due to the use of very different olfactory tasks and odors in previous 
studies. However, some studies support the role of entorhinal cortex in OI 
(Eichenbaum et al., 1983, Wilson et al., 2007).  Based on our findings, the entorhinal 
cortex is specifically involved in OI, and hence damage to this structure will affect OI 
performance directly as well as also compromise input to the hippocampus, another 
structure important for both OI and in MCI and AD. 
 
Hippocampal pathology has also been connected with OI deficits (Lojkowska et al., 
2011), and the present work supports the hypothesis that the hippcampus is 
specifically involved in higher level processing of olfactory information (Staubli et al., 
1984). The larger number of activated voxels and mean maximum parameter 
estimate values in the anatomical hippocampal ROI, combined with a positive BOLD 
signal for identified odors, and a negative BOLD signal for non-identified odors in the 
functional ROI, further substantiate this claim. Previous research has also reported 
activation in the right hippocampus during OI tasks (Murphy et al., 2003, Suzuki et 
al., 2001), and during odor recognition memory (Jones-Gotman and Zatorre, 1993, 
Zatorre et al., 2000). The role of hippocampus in OI may be related to its role in 
odor memory function. 
 
MTL is important for both episodic and semantic memory (Manns et al., 2003, Squire 
and Zola, 1998), but the majority of studies report that episodic memory mainly 
relies on the hippocampal formation (Nadel and Moscovitch, 1997, Reilly, 2001, 
Tulving and Markowitsch, 1998). We believe that the hippocampal activation seen in 
our experiment stems from its role in episodic and semantic memory (discussed in 
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section 5.2.1.). Episodic memory is involved in OI because odors are strongly 
connected to the episodes when the odor encoding took place. Recently, an episodic 
odor memory test (three versions exist) was developed by Professor Maria Larsson 
and colleagues at Karolinska Institutt, Sweden. This is a modified version of the 
SSIT. The test includes an encoding phase, and then the odor is presented, 
intermixed with a number of new odors that were not presented earlier. The test is 
used in the Swedish National Study on Aging and Care (SNAC), but no study using 
this test has been published yet. Based on our findings, we believe such a test could 
be used to elucidate the role of hippocampus in OI. However, such a test may be too 
difficult to perform for the patients with early AD. 
 
5.2.1.     OI and semantic memory 
 
OI is typically categorized under semantic memory, since the task depends on 
previously learned odor-name associations, and successful retrieval of these 
associations (Murphy et al., 1997, Oberg et al., 2002). In the total group of patients 
and controls, there was a significant correlation for both B-SIT and SSIT with the 
stereognosis test, verbal memory (Ten Word Test, total recall and delayed recall) and 
MMSE (Paper IV). All this tests have a semantic component, supporting the theory 
that OI relies on semantic memory (Murphy et al., 1997, Oberg et al., 2002) and that 
better semantic and verbal memory abilities are associated with better OI abilities 
(Economou, 2003, Larsson et al., 2000). 
 
Reduced OI may sometimes arise from a problem with selecting the correct label 
from a number of related alternatives. Based on our findings it is clear that test 
methodology employed for B-SIT and SSIT may affect performance. Unpublished 
data from Paper IV, investigated the OI mistakes in the SSIT. In healthy controls the 
most common odors mistaken were lemon (35.5 %), turpentine (32.4%), apple 
(32.4%) and pineapple (35.5 %) (Unpublished data, Paper IV). These results are 
very similar to a study from a British population, where lemon, turpentine, apple and 
cloves were the odors most commonly mistaken (Neumann et al., 2012). These 
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authors suggested that when the distracter odor names given in the multiple choice 
task are too similar, then OI becomes more difficult (Doty, 2003). This is nicely 
exemplified by the odor apple, where the distracters are orange, peach and lemon. 
The odor in SSIT with the highest OI score on the other hand is fish, correctly 
identified by 96.7 %, which has the distracters bread, cheese and ham. The use of 
similar or more distinct distracters has also previously been shown to affect the 
performance of olfactory tests (Engen, 1987), and another study with more 
contrasted distracters improved the test results (Gudziol and Hummel, 2009). On the 
other hand, the difficulty of cued OI increases with the number of verbal cues 
presented (Negoias et al., 2010), again pointing to how OI performance is influenced 
by the actual task the participant is performing.  
 
However, B-SIT frequently uses the alternative "fruit", which is a very general term. 
For example for item 12 (odor onion) the alternatives are chocolate, banana and 
fruit. Since banana is a fruit, giving an alternative in this manner may be misleading 
for the person tested. In Paper II we decided to replace all the "fruit" alternatives 
occurring in B-SIT (three items). These changes did not improve the overall scores 
on the test, or even the scores on the specific test alternative. Thus there was 
actually no advantage with the distractor "fruit", except that it was a convenient 
distractor to replace with "none/other". In my opinion the distracters used in the B-
SIT items are in general more different than for SSIT. One example is pineapple; in 
B-SIT (item 9), the distracters are smoke, whiskey and onion, whereas in SSIT (item 
13), the distractors are pear, plum and peach. I believe this is a benefit of the B-SIT 
test compared to the SSIT. 
 
5.3.  The role of OI in AD 
 
Based on the present work, the OI deficit in aMCI and early dementia in AD appears 
to be of central origin and not due to deficits in odor perception per se. We did not 
find significant differences between persons with aMCI or early dementia in AD and 
controls, in the performance of SSDT. However, we did not investigate odor 
detection abilities, but we observed that "intact" and "impaired OI" groups performed 
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equally well on the SSDT (paper IV), and this indicates no sensory deficit in these 
patients. This is in line with previous studies of OI where deficits have been shown to 
occur in the early stage of the diseases, whereas the ability to detect odors is 
affected later (Christen-Zaech et al., 2003, Hedner et al., 2010, Larsson et al., 2000, 
Nordin et al., 1997, Rahayel et al., 2012, Serby et al., 1991). A possible explanation 
for the relatively intact discrimination abilities seen in our study could be that the 
patients in study IV were still in an early stage of AD. 
 
It is widely debated whether the earliest pathological changes in AD are related to 
damage in the peripheral part of the olfactory system, or more central structures of 
the brain. Many studies have reported significant histological changes in peripheral 
olfactory structures (Buschhuter et al., 2008, Kovacs et al., 2001, Tabaton et al., 
1991, Talamo et al., 1989) in patients with OI dysfunction in AD. However, we did 
not measure the olfactory bulb volume, but studied the more central structures of 
the brain. In Study IV, OI performance (based on SSIT and B-SIT) was associated 
with a significantly reduced volume of hippocampus in patients with aMCI and early 
dementia in AD. Hippocampal volumes have also been found to correlate significantly 
with OI performance in previous studies (Lojkowska et al., 2011, Murphy et al., 
2003, Smitka et al., 2011), and support a specific role of hippocampus in OI. Thus it 
may be reasonable to suggest that OI deficits in patient groups result from early MTL 
changes. Unpublished data support these findings. To investigate the neuronal 
correlates to OI in neurodegeneration, we conducted a similar fMRI study to that 
reported in paper III, with the participants in paper IV (18 patients and 29 controls 
had completed the fMRI experiment). In this study, an automatically-controlled 
olfactometer was used, and responses were logged according to identified odors or 
non-identified odors in the fMRI-experiment. Significance was tested at the voxel 
level z= 2.3, and the cluster thresholding at p<0.05 (contrast identified odors> non-
identified odors). In both patients and controls, the unpublished results show 
bilateral activation in insula, cingulate gyrus and cerebellum. In addition activation in 
left amygdala was seen in both patients and controls. Interestingly, no activation was 
observed in hippocampus or entorhinal cortex during OI in aMCI or AD patients. In 
healthy elderly individuals, activation was seen in the left entorhinal cortex. 
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Furthermore, we used a whole brain analysis using voxel based statistics, z=2.3 and 
p<0.05, uncorrected (contrast identified>non-odors in controls>patients). Activation 
was seen bilaterally in entorhinal cortex and hippocampus in the healthy elderly (z 
between 1.7 and 1.9). These findings support that changes in the brain in AD 
patients can be observed in relation to olfactory function, as shown in other imaging 
studies (Bahar-Fuchs et al., 2010, Forster et al., 2010, , Kareken et al., 2001, Murphy 
et al., 2003, Wang et al., 2010). It also supports the changes in MTL in early AD 
causing OI deficits. 
 
Results from earlier work have demonstrated that the deficits in olfactory function in 
MCI and AD may occur prior to the advent of typical cognitive dysfunction and 
behavioral disturbances (Bacon et al., 1998, Devanand et al., 2000, Graves et al., 
1999). In the total group of patients and controls in Study IV there was a correlation 
between general cognition (measured with MMSE), verbal memory (Ten Word Test; 
total recall and delayed recall) and hippocampal volume, as described in section 
5.2.1. No correlation was found between the rey-test (figure copying) and 
hippocampus. But in the subgroups of patients with "intact" or "impaired" OI, there 
was no difference in performance on the neuropschychological tests, but a significant 
difference was seen for the hippocampal volume. Based on this, we concluded that 
OI ability is a better predictor of hippocampal volume loss in patients with aMCI or 
early dementia in AD, than the neuropsychological tests used in this study. It is 
possible that the olfactory modality is more sensitive to changes in hippocampal 
volumes than input from other modalities, since olfactory input is just a few synapses 
away from the peripheral sensory organ. Alternatively, the fact that OI draws on 
both episodic and semantic memory may render it more dependent on the 
hippocampus. However, these theories are speculations. Unfortunately, we do not 
have measures for entorhinal cortex, which would have been particular interesting to 
explore, especially the association between entorhinal thickness/volume and 
hippocampal volume. 
 
In paper III we reported increased activation during OI in the cortical regions sub 
serving sensory systems other than olfaction, e.g. primary visual and auditory 
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cortices, and higher order somatosensory regions. Such activation may represent 
cortical reinstatement, i.e. activation of cortical regions involved in encoding of 
specific sensory details during previous experiences with the identified odors 
(Eldridge et al., 2000, Gottfried et al., 2004, Johnson and Rugg, 2007, Vaidya et al., 
2002). Because OI is a complex process, it requires a network of structures in the 
brain which support specific memories, semantic knowledge, sensory details, earlier 
experience, feelings, and thoughts about the presented odor. Dependence on such a 
distributed network of brain regions may render OI particularly vulnerable to 
neurodegenerative changes. This may imply that OI tests may be tests of 
disconnection, and not only MTL dysfunction. One method suited to study white 
matter connections in the brain is Diffusion Tensor Imaging (DTI). In a recent study, 
significant DTI differences between stable MCI versus progressive MCI subjects were 
observed. Fractional anisotropy (FA) was significantly higher in controls compared to 
MCI in networks involving the corpus callosum, right temporal, and frontal pathways 
(Haller et al., 2010). In our unpublished fMRI data, the BOLD-responses were 
generally much weaker, and limited to smaller regions in the patients compared to 
the healthy individuals, as shown in a recent study (Wang et al., 2010). Our findings 
reflect how OI is dependent on MTL, though an entire network of structures is 
involved, and damage to this system in AD may cause the OI deficits. 
 
5.3.1.     The predictive role of OI in AD 
 
In the current setting, the success of an OI test as a screening tool depends on its 
ability to predict the development of neurodegenerative diseases such as AD. In 
paper IV we described that the B-SIT score did not differentiate between patients 
with aMCI and those with early dementia in AD at baseline (p >0.4). However, 
prospectively after the 6-18 months follow up, a significant difference in B-SIT score 
was found between patients that progressed to AD compared to those who remained 
stable in their cognitive functions. These results indicate that a low B-SIT score could 
be a predictor for more rapid development of AD, detectable even in a small sample. 
However, similar results were not obtained with SSIT, and this may be caused by the 
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differences between B-SIT and SSIT discussed in section 5.1. This discrepancy 
between two OI tests may explain the reported contradictory evidence for the OI 
tests as predictors for developing AD, where mainly two longitudinal studies have 
demonstrated OI tests as predictors of conversion from MCI to dementia/AD 
(Devanand et al., 2000, Lojkowska et al., 2011). These studies used the UP-SIT test, 
and the SSIT (with presentation of four figures for each smell). Many cross-sectional 
studies of OI in AD/MCI have been performed, but more longitudinal studies are 
required to evaluate the value of OI testing as a predictor of conversion to AD.  
 
Earlier studies have suggested a possible clinical relevance of unawareness related to 
olfactory dysfunction. In paper IV we reported that the study patients had poor 
insight regarding their OI (k=0.21), which is in agreement with data reported by 
Nordin et al. and Doty et al. (Doty and Ferguson-Segall, 1987, Nordin et al., 1995), 
which found unawareness of reduced olfactory function in MCI, early AD and AD 
patients. In Study IV, no correlation between the diagnosis at 6-18 months follow up, 
or subjective report of olfactory function in the patients was found, in agreement 
with previous studies (Bahar-Fuchs et al., 2011, Djordjevic et al., 2008). Conversely, 
some researchers have claimed that patients with low olfactory scores and reduced 
awareness of their own OI dysfunction were more likely to develop AD (Devanand et 
al., 2000, Tabert et al., 2002).  
  
As suggested earlier, olfactory testing together with neuropsychological tests may 
help to more accurately predict whether or not a patient with MCI will convert to 
dementia/AD (Devanand et al., 2000, Lojkowska et al., 2011). Our group of patients 
was too small to use more sophisticated statistical methods to determine the 
contribution of various OI and neuropsychological tests to predict AD development. 
However, our findings suggested that OI ability is related more to hippocampal 
volume loss than the neuropsychological tests used in our study. Since hippocampal 
volume is a sensitive marker for the risk of developing AD, replication of our findings 
in larger populations would verify whether OI is a more sensitive marker of 
hippocampal volume than neuropsychological tests. If so, OI may be a potential 
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inexpensive and accessible biomarker for hippocampal volume even without MRI 
measurements.  
 
5.4.   Methodological considerations 
 
We used three different types of test to investigate olfactory function; psychophysical 
tests (Paper I-IV), fMRI (Paper III) and structural MRI (in combination with 
psychophysical tests) (Paper IV). Methodological issues and challenges with these 
types of methods are discussed below. 
 
The studies included in this thesis are cross-sectional studies. However, study IV had 
longitudinal aspects, though the sample size was restricted. For future research, both 
longitudinal studies and larger samples of patients are required to obtain more 
knowledge about the olfactory hypotheses in AD.  
 
In Study I, patients with AD diagnosis according to the NINCDS-ADRDA criteria were 
included (McKhann et al., 1984). In Study IV, patients fulfilling the accepted 
diagnostic criteria for aMCI (McKhann et al., 1984, Petersen et al., 1999, Winblad et 
al., 2004) were included. The overall group of patients (both aMCI and early 
dementia in AD) was divided into two subgroups for further analysis based on their 
OI abilities according to performance on B-SIT and SSIT (Study IV). In the clinic, it is 
not easy to clearly differentiate aMCI from early dementia in AD, which is one of the 
reasons the Dubois research criteria consider aMCI an early expression of AD (Dubois 
et al., 2007). Neither was there a significant difference in OI performance between 
the aMCI patients and the patients with early dementia in AD. Therefore, we decided 
to group the aMCI and early dementia in AD patients together as they probably all 
represent patients in an early stage of AD and because the sample size was small. 
However, we can not be sure that all aMCI patients would progress to AD. 
 
In Papers I and II, psychophysical tests were used to measure olfactory function. 
Olfactory screening tests are developed to be brief and easy. The B-SIT may be 
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administered in less than 5-6 minutes, but has a lower reliability compared to the UP-
SIT (Doty et al., 1996). It is necessary to state that Studies I and II are not a 
validation of the B-SIT. Study II is rather an example of how a modification of the 
test can fit the Norwegian population better for research purposes, and possibly for 
patients with neurodegenerative diseases. Validation of the tests requires studies in 
larger populations of individuals performing the OI tests. 
 
In Paper III we used fMRI and a home-built olfactometer to measure activity in the 
brain during OI. There are several challenges to studying olfaction with fMRI. Firstly, 
odors are not quantifiable, and it is therefore impossible to know whether the 
subjects were presented with exactly the same amount of perceived stimulus. Also 
each individual’s experiences with an odor may vary based on previous encounters 
with the odors. Moreover, there is a connection between breathing, sniffing and 
smelling (Johnson et al., 2006, Mainland and Sobel, 2006).The use of a high-
sensitivity measure of nasal airflow (for example pneomatotachograph) could have 
been used to record sniffing in the fMRI experiment, because sniffing modulates and 
drives activity through the olfactory system. Furthermore, there was a lack of 
synchronization between odor onset and respiratory cycle in study III. Inclusion of 
continuous breathing monitoring and odor presentation at the time of inspiration 
would have improved the study. However, this was not possible to implement 
properly with the olfactometer, since the air with the odor was delivered via tubes, 
and not directly into the nose as in olfactory event-related potentials (oERPs), and 
there was no feedback connecting respiration and odor delivery. 
 
The benefit of an olfactory fMRI-method is its non-invasive nature, and the 
opportunity to study neuronal correlates to different types of olfactory tasks in both 
healthy participants and patient groups. Major challenges in the literature of olfactory 
studies include large differences in experimental design, including odor selection and 
number, odor presentation intervals, analysis methods, and scan protocols. Also 
cultural differences with regard to odor repertoire may play a role. These differences 
make it difficult to directly compare the results across studies. Another issue in our 
fMRI results is the use of liberal statistics. It is well known that there are significant 
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between region differences in the amplitude of the BOLD signal (see e.g. Aguirre et 
al., 1998, Birn et al., 2001, Handwerker et al., 2004, Miezin et al., 2000), and that 
BOLD signals from the MTL, and in particular the entorhinal cortex, have lower Z 
values than for instance in the cortex (Ojemann et al., 1997, Tabert et al., 2007). 
The reason for this is a complex combination of MRI technical and local anatomical-
physiological properties of the entorhinal cortex, and perhaps also related specifically 
to olfactory stimuli. MR technical issues affecting the BOLD signal in entorhinal 
activity are linked to a susceptibility artefact (Gorno-Tempini et al., 2002, Ojemann et 
al., 1997) and coil effects (Kaza et al., 2011).  
 
In paper IV, we used the Software NeuroQuant to perform automatic segmentation 
of brain structural volumes. Fully automatic segmentation of brain structures has 
several advantages; it is fast and requires very little manual input (Brewer, 2009). 
However, such a method may have several weaknesses. Automatic segmentation 
without manual intervention could lead to more mis-segmentation, and thus 
inaccurate volume calculation. However, Neuroquant has been compared with expert 
manual computer-aided segmentation, and the structural volumes from each method 
were found to correlate significantly with each other (Brewer, 2009). The same study 
also validated the program´s ability to differentiate between healthy controls and the 
atrophy of brain structures affected early in AD patients, thus supporting the validity 
of the volumetric measures in this study. Several studies have used automated 
segmentation with satisfactory results (Colliot et al., 2008, Chupin et al., 2009). In 
addition, no measurements of the volume of entorhinal cortex were done, and should 
be included in further studies of OI. 
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6.0. Conclusions 
 
In this thesis, olfactory function was investigated with imaging methods and 
neuropsychological tests in Norwegian cohorts. 
The main results of the thesis are as follows: 
 
1) Both B-SIT and SSIT are well-suited for use in Norwegian cohorts. Both tests 
showed a highly significant difference in olfactory performance in OI between 
patients with AD, patients with aMCI, and patients with early dementia in AD, 
compared to healthy elderly. Both tests are inexpensive, rapid, and easy to 
administer in the clinic. 
 
2) Introduction of a placebo and the alternatives "none/other" seem to be a more 
appropriate approach for olfactory testing in healthy subjects and patients with 
neurodegenerative diseases. The replacement of the item "turpentine" with a 
placebo resulted in an improved score for the item in a Norwegian setting. 
 
3) During an OI task activation is seen in a network of structures in the brain, and 
hippocampus and entorhinal cortex appear to be important for the processing of 
successful OI in healthy young subjects. 
 
4) aMCI and early dementia in AD patients with impaired OI function have 
significantly more reduced hippocampal volumes than patients with relatively intact 
OI function. OI-tests may help distinguish those patients who are more advanced in 
the development of early AD. 
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6.1.  What the future may bring 
 
When the mechanism of olfactory dysfunction is well-understood and well-
established, olfactory deficits can become a useful biomarker to include in a test 
battery for AD. I believe we need to perform more longitudinal studies, with 
standardized methods and neuroimaging in a large group of patients with MCI and 
relatively intact OI function. I believe this is important in understanding why the 
disease particularly affects olfactory function, and will provide answers to the 
olfactory hypothesis of OI in AD. I believe that a psychophysical OI test, in addition 
to structural MRI, will be a promising investigative combination providing useful 
information about OI deficits in the early phase of the disease. 
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